NCT04161547View on ClinicalTrials.gov

Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

June 1, 2020

Study Completion Date

June 1, 2020

Conditions
Asthma; Allergic Rhinitis
Interventions
DRUG

CSPCHA115 100 mg; Matching placebo 100 mg

CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.

DRUG

CSPCHA115 200 mg; Matching placebo 200 mg

CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.

DRUG

CSPCHA115 400 mg; Matching placebo 400 mg

CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.

DRUG

CSPCHA115 600 mg; Matching placebo 600 mg

CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.

Trial Locations (1)

100000

Beijing Anzhen Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT04161547 - Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers | Biotech Hunter | Biotech Hunter